Peter Feldman Highlights Hereditary Factor X Deficiency Day and the Impact of Coagadex Production at Kedrion’s BPL Site
Peter Feldman, Director of Pharmaceuticals and Healthcare at Queen’s House Consulting, shared on LinkedIn:
”On Hereditary Factor X Deficiency Day (10/10), I have been visiting Kedrion’s BPL site in Elstree, UK, meeting some of the one-in-ten-million people* who manufacture Coagadex factor X concentrate for the one-in-one-million people** living with factor X deficiency.
Great to meet friends old and new who maintain supply of this ultra-orphan drug product, purified from human blood plasma (coincidently, it is also International Plasma Awareness Week).
Sorry not to tag you all, but it would exceed my character-count allowance!
In an age where pharma companies are simultaneously celebrated for their innovation and castigated for their commercialism, it important to recognise the needs of people who live life to the max alongside their coagulation factor deficiency and the individual commitment of people across the plasma industry who strive to facilitate this.
*approximately 8 billion people on the planet and approximately 1000 people on the Elstree site = 1 in 10 million (rounded up).”
Read the full factsheet here.
Stay updated with Hemostasis Today.
-
Oct 11, 2025, 09:06Natalia Peres Martinez - Surgical Bleed: Replacing Gut Feeling With Guided Thinking
-
Oct 11, 2025, 09:00Muhammad Ali - Hematology In Pakistan: The Silent Revolution In Diagnosis And A Blueprint For Growth
-
Oct 11, 2025, 08:50Robert Zeiser: New Insights and Timeless Lessons in Transplantation
-
Oct 11, 2025, 08:39Mildred Lundgren: These 5 Proposals Are A Clear Road Map for The Future And We Support Them Wholeheartedly
-
Oct 11, 2025, 08:33RPTH Journal: Does Fasting Affect Anticoagulant Therapy? - The Effects Of Fasting During Ramadan
-
Oct 12, 2025, 10:14Hatim Lokhandwala: Landmark HI-PRO Trial Redefines VTE Treatment Guidelines
-
Oct 11, 2025, 18:47Endovascular Today: SYMPHONY-PE Trial and Advances in Pulmonary Embolism Treatment
-
Oct 11, 2025, 08:49Rodrigo Assar: We Are Pushing the Boundaries by Using Computational Approaches
-
Oct 11, 2025, 08:48Deborah Wild: Thrilled to See GeneVentiv Selected for The NIH NHLBI Catalyze Program
-
Oct 11, 2025, 08:34Ivo Francischetti and Colleagues on Glycoprotein VI Contributing to Platelet Activation in HIT
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 7, 2025, 13:06Bobur Kholikov on iFlash Thrombosis Panel – D-Dimer
-
Oct 7, 2025, 03:502025 Nobel Prize: A Milestone for Autoimmunity Research - Awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi
-
Oct 11, 2025, 08:57Jeff June - Seeing The Invisible: How Spatial Biology Is Opening A New Chapter In Stroke Care
-
Oct 11, 2025, 08:11Khaled Musallam: Honored to Be Featured for The 7th Year in A Row in The World’s Top 2% Most-Cited Scientists
-
Oct 11, 2025, 08:07Britta Diebel: This Has Been An Intense, Good Week, Although IPAW Actually Lasts All Year Long
-
Oct 10, 2025, 03:10Marilena Vrana: Plasma-Derived Medicines Are a Clear Example of Why A One-Size-Fits-All Approach Won’t Work
-
Oct 10, 2025, 03:07Nancy Di Salvo: It's IPAW 2025, How Could I Not Take a Moment to Thank Every Single Plasma Donor Out There?